Please login to the form below

Not currently logged in
Email:
Password:

AZ said to be eyeing Forest takeover bid

Financial Times says pharma companies are in early negotiations

AstraZeneca (AZ) is considering a takeover bid for Forest Laboratories of the US, according to a Financial Times report which cites people close to two companies.

The rumour comes shortly after recently appointed Forest chief executive Brenton Saunders announced a major shake-up of the company's operations, including a cost-cutting programme aimed at trimming $500m off its cost base and a $400m share buyback.

The FT suggests AZ financial advisers recently met the senior management at Forest to discuss a cash offer for the company, which is valued at around $15bn, but that the negotiations are still in very preliminary stages.

At that valuation, any bid for Forest could rival the $15.6bn AZ paid for Medimmune five years ago to boost its biologics pipeline, a deal which some have suggested was priced too high.

One of the draws for AZ is that Forest's product pipeline is pretty closely aligned with its own R&D priorities, with a particular focus on treatments for central nervous system (CNS) disorders as well as cardiovascular and respiratory medicine and infectious diseases.

After several pipeline setbacks, AZ has signed a string of acquisition and licensing deals under CEO Pascal Soriot, who took over the reins of the pharma giant last year with a pledge to streamline and reform the business.

Last month the company agreed to pay $440m to buy antibody-drug conjugate (ADC) specialist Spirogen, while in August it bought cancer company Amplimmune in a deal valued at up to $500m. Earlier this year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as US biotechs AlphaCore Pharma and Omthera Pharmaceuticals.

Analysts suggested that the timing of Forest's restructuring drive - in particular with share buyback - may be a defensive measure to make sure it secures a premium price in any buy-out of the business.

Article by
Phil Taylor

4th December 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics